Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting1
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

recruiting133%
completed133%
not_yet_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer

NCT06869629
recruitingnot_applicable

Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer

NCT04671511
completed

Ideal Marker for Targeted Axillary Dissection

NCT04580251

Clinical Trials (3)

Showing 3 of 3 trials
NCT06869629Not Applicable

Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer

Not Yet Recruiting
NCT04671511Not Applicable

Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer

Recruiting
NCT04580251

Ideal Marker for Targeted Axillary Dissection

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3